COPD (Chronic Obstructive Pulmonary Disease)Phase 3THARROSNCT06283966

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

A Phase 3 study testing BGF MDI 320/14.4/9.6 μg and GFF MDI 14.4/9.6 μg in people with COPD (Chronic Obstructive Pulmonary Disease), run by AstraZeneca at 922 sites in 37 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts

Official record

Search all trials

Trial summary

This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk. Read more about this study

Who is it for?: Ages 40 to 80 years
Conditions the study is for: COPD (Chronic Obstructive Pulmonary Disease)
What is being tested?: BGF MDI 320/14.4/9.6 μg and GFF MDI 14.4/9.6 μg
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 5,250 participants
Where: 922 sitesin 37 countries
Study dates: 21 Feb 2024to 3 Dec 2027
Phase: Phase 3
Are there results?: Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 40 to 80 years
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Male or female participants must be 40 to 80 years of age inclusive, at the time of signing
the ICF.
Demonstrate acceptable MDI administration technique at Visit 1 (V1) and Visit 2 (V2)
A diagnosis of COPD confirmed by a post-bronchodilator FEV1/FVC ratio < 70%
at V1.
Current or former smokers with a history of at least 10 pack-years of cigarette smoking;

Show all 32Show fewer

defined as (number of cigarettes per day/20) x number of years smoked. Previous smokers are defined as those who have stopped smoking for at least 6
months prior to V1.
A baseline peripheral blood eosinophil count of ≥ 100 cells/mm3 assessed at Visit 1 by
the central laboratory
A CAT score of ≥ 10 at Visit 1.
Participant must fulfill at least 1 of the 4 CV disease/risk factor criteria below [(a), (b),
(c), or (d)]:
: Established CV Disease
: Combination of CV risk factors:
Hypertension
Diabetes Mellitus
Chronic Kidney Disease
Dyslipidemia
Obesity
: High risk of CV disease determined using an established CV risk assessment
tool.
: CT coronary Artery Calcification
Willing and, in the opinion of the investigator, able to adjust current COPD therapy, as
required by the protocol.
Willing to visit at the study site or participate in virtual visits as required per the protocol
to complete all study assessments.
A female is eligible to enter and participate in the study if the female is of:
Non-childbearing potential: either permanently sterilized or who are post-menopausal.
Childbearing potential: has a negative serum pregnancy test at V1 and must use one
highly effective form of birth control.
Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in the protocol.

Who cannot join

Active diagnosis of asthma within the past 5 years (previous diagnosis as a child or adolescent are eligible), asthma-COPD overlap, or any other chronic respiratory disease other than COPD such as alpha-1 antitrypsin deficiency, active tuberculosis, lung fibrosis, sarcoidosis, interstitial lung disease, and pulmonary hypertension.
End-stage renal disease requiring renal replacement therapy
History of heart or lung transplant or actively listed for heart or lung transplant.
Implanted left ventricular assist device or implant anticipated in < 3 months.
History of lung cancer and/or treatment for lung cancer within the 5 years prior to Visit 1.
Unstable or life-threatening cardiac disease - participants with any of the following at Visit 1 would be excluded:

Show all 19Show fewer

An MI or unstable angina in the last 8 weeks
Unstable or life-threatening cardiac arrhythmia requiring intervention in the last 8 weeks.
NOTE: Any participant who experiences unstable or life-threatening cardiac disease during the run-in period will be excluded but can be rescreened 8 weeks after the resolution of the event.
Pneumonia and/or moderate or severe COPD exacerbation that has not resolved at least 8 weeks prior to Visit 1
Any life-threatening condition, including malignancy, with a life expectancy < 5 years, other than CV disease or COPD, that might prevent the participant from completing the study.
Use of maintenance ICS treatment within the past 12 months.
Unable to abstain from protocol-defined prohibited medications
Participation in another clinical study with a study intervention administered in the last 30 days or 5 half-lives, whichever is longer prior to Visit 1 (any other investigational product that is not identified in protocol is prohibited for use during the duration of the study).
Participants with a known hypersensitivity to LAMA, LABA or ICS or any component of the MDI.
Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
Previous randomization in the present study.
For females only - currently pregnant (confirmed with positive pregnancy test) or breastfeeding

Trial locations and contacts

922 sites in 37 countries. Contact the study team or a site near you to ask about taking part.

AstraZeneca Clinical Study Information Center contact

1-877-240-9479

information.center@astrazeneca.com

Country

City, postcode or hospital

Sites recruiting now only

922 sites in 37 countries

United States235 sites, 135 recruiting

Research Site
Abilene, Texas, 79606
Recruiting
Research Site
Albany, New York, 12205
Recruiting
Research Site
Albany, New York, 12208
Withdrawn
Research Site
Albuquerque, New Mexico, 87109
Withdrawn
Research Site
Amarillo, Texas, 79106
Withdrawn
Research Site
Anderson, South Carolina, 29621
Recruiting
Research Site
Ann Arbor, Michigan, 48109
Recruiting
Research Site
Apple Valley, California, 92307
Withdrawn
Research Site
Athens, Alabama, 35611
Terminated
Research Site
Aurora, Colorado, 80012
Recruiting
Research Site
Austin, Texas, 78704
Terminated
Research Site
Beavercreek, Ohio, 45431
Terminated
Research Site
Blue Ash, Ohio, 45242
Recruiting
Research Site
Boise, Idaho, 83706
Terminated
Research Site
Boston, Massachusetts, 02115
Recruiting
Research Site
Bountiful, Utah, 84010
Withdrawn
Research Site
Boynton Beach, Florida, 33435
Recruiting
Research Site
Bradenton, Florida, 34209
Recruiting
Research Site
Bronxville, New York, 10708
Withdrawn
Research Site
Brooklyn, New York, 11220
Terminated
Research Site
Brownsville, Texas, 78520
Recruiting
Research Site
Camp Hill, Pennsylvania, 17011
Recruiting
Research Site
Canoga Park, California, 91303
Suspended
Research Site
Cape Coral, Florida, 33990
Recruiting
Research Site
Castroville, California, 95012
Recruiting
Research Site
Charleston, South Carolina, 29414
Recruiting
Research Site
Charleston, South Carolina, 29414
Terminated
Research Site
Chattanooga, Tennessee, 37421
Recruiting
Research Site
Chicago, Illinois, 60607
Recruiting
Research Site
Clearwater, Florida, 33756
Recruiting
Research Site
Clearwater, Florida, 33765
Recruiting
Research Site
Cleveland, Ohio, 44130
Terminated
Research Site
Columbia, South Carolina, 29201
Withdrawn
Research Site
Columbus, Ohio, 43215
Recruiting
Research Site
Columbus, Ohio, 43235
Terminated
Research Site
Crystal River, Florida, 34429
Recruiting
Research Site
Cudahy, Wisconsin, 53110
Recruiting
Research Site
Cullman, Alabama, 35058
Recruiting
Research Site
Cutler Bay, Florida, 33189
Suspended
Research Site
Dallas, Texas, 75225
Terminated
Research Site
Dallas, Texas, 75235
Terminated
Research Site
Dallas, Texas, 75254
Recruiting
Research Site
Denver, Colorado, 80228
Recruiting
Research Site
DuBois, Pennsylvania, 15801
Withdrawn
Research Site
Edgewater, Florida, 32132
Recruiting
Research Site
El Paso, Texas, 79902
Terminated
Research Site
El Paso, Texas, 79902
Recruiting
Research Site
Elizabethton, Tennessee, 37643
Terminated
Research Site
Englewood, Colorado, 80110
Terminated
Research Site
Exton, Pennsylvania, 19341
Withdrawn
Research Site
Fairhope, Alabama, 36532
Terminated
Research Site
Fayetteville, Georgia, 30214
Terminated
Research Site
Fayetteville, North Carolina, 28303
Terminated
Research Site
Flint, Michigan, 48504
Recruiting
Research Site
Forney, Texas, 75126
Recruiting
Research Site
Fort Lauderdale, Florida, 33308
Recruiting
Research Site
Fort Myers, Florida, 33912
Terminated
Research Site
Franklin, Tennessee, 37067
Recruiting
Research Site
Fremont, Nebraska, 68025
Recruiting
Research Site
Gaffney, South Carolina, 29340
Recruiting
Research Site
Garden Grove, California, 92844
Recruiting
Research Site
Gardena, California, 90247
Terminated
Research Site
Georgetown, Texas, 78633
Terminated
Research Site
Gilbert, Arizona, 85296
Recruiting
Research Site
Glen Burnie, Maryland, 21061
Withdrawn
Research Site
Glendale, Arizona, 85308
Withdrawn
Research Site
Grand Island, Nebraska, 68803
Recruiting
Research Site
Grants Pass, Oregon, 97527
Terminated
Research Site
Greensboro, North Carolina, 27405
Recruiting
Research Site
Greenville, North Carolina, 27834
Recruiting
Research Site
Gulfport, Mississippi, 39503
Recruiting
Research Site
Hialeah, Florida, 33012
Terminated
Research Site
Hialeah, Florida, 33013
Terminated
Research Site
Hollywood, Florida, 33024
Recruiting
Research Site
Homestead, Florida, 33033
Recruiting
Research Site
Houston, Texas, 77002
Recruiting
Research Site
Houston, Texas, 77008
Terminated
Research Site
Houston, Texas, 77024
Terminated
Research Site
Houston, Texas, 77025
Terminated
Research Site
Houston, Texas, 77074
Withdrawn
Research Site
Houston, Texas, 77079
Recruiting
Research Site
Houston, Texas, 77084
Terminated
Research Site
Houston, Texas, 77089
Recruiting
Research Site
Houston, Texas, 77207
Terminated
Research Site
Huntersville, North Carolina, 28078
Recruiting
Research Site
Huntsville, Alabama, 35801
Terminated
Research Site
Inglewood, California, 90301
Recruiting
Research Site
Kansas City, Missouri, 64116
Suspended
Research Site
Katy, Texas, 77450
Withdrawn
Research Site
Katy, Texas, 77493
Withdrawn
Research Site
Kerrville, Texas, 78028
Terminated
Research Site
Kingwood, Texas, 77339
Recruiting
Research Site
Kissimmee, Florida, 34741
Withdrawn
Research Site
Kissimmee, Florida, 34746
Recruiting
Research Site
La Mesa, California, 91942
Recruiting
Research Site
La Palma, California, 90623
Recruiting
Research Site
Lafayette, Louisiana, 70508
Recruiting
Research Site
Lake City, Florida, 32055
Terminated
Research Site
Lake City, Florida, 32055
Recruiting
Research Site
Lake Worth, Florida, 33467
Recruiting
Research Site
Lakeland, Florida, 33805
Recruiting
Research Site
Lakeland, Florida, 33813
Recruiting
Research Site
Las Vegas, Nevada, 89101
Recruiting
Research Site
Las Vegas, Nevada, 89102
Terminated
Research Site
Las Vegas, Nevada, 89119
Terminated
Research Site
Las Vegas, Nevada, 89121
Recruiting
Research Site
Lawrence, New Jersey, 08648
Withdrawn
Research Site
Lewisville, Texas, 75057
Suspended
Research Site
Lexington, Kentucky, 40503
Recruiting
Research Site
Liberty, Missouri, 64068
Withdrawn
Research Site
Lincoln, Nebraska, 68510
Withdrawn
Research Site
Lomita, California, 90717
Recruiting
Research Site
Long Beach, California, 90815
Recruiting
Research Site
Los Alamitos, California, 90720
Terminated
Research Site
Loxahatchee Groves, Florida, 33470
Withdrawn
Research Site
Marion, Ohio, 43302
Recruiting
Research Site
Massapequa, New York, 11758
Recruiting
Research Site
McAllen, Texas, 78504
Recruiting
Research Site
McKinney, Texas, 75069
Recruiting
Research Site
Medford, Oregon, 97504
Recruiting
Research Site
Mesa, Arizona, 85206
Recruiting
Research Site
Mesa, Arizona, 85213
Recruiting
Research Site
Miami, Florida, 33155
Recruiting
Research Site
Miami, Florida, 33175
Recruiting
Research Site
Miami, Florida, 33175
Terminated
Research Site
Miami Lakes, Florida, 33016
Recruiting
Research Site
Milwaukee, Wisconsin, 53228
Recruiting
Research Site
Milwaukee, Wisconsin, 53295
Terminated
Research Site
Mission Viejo, California, 92691
Recruiting
Research Site
Missoula, Montana, 59808
Recruiting
Research Site
Mobile, Alabama, 36608
Recruiting
Research Site
Monroe, Louisiana, 71201
Recruiting
Research Site
Morehead City, North Carolina, 28557
Recruiting
Research Site
Morgantown, West Virginia, 26505
Terminated
Research Site
Morristown, Tennessee, 37813
Terminated
Research Site
Mullica Hill, New Jersey, 08062
Recruiting
Research Site
Naples, Florida, 34102
Recruiting
Research Site
New Windsor, New York, 12553
Recruiting
Research Site
New York, New York, 10036
Recruiting
Research Site
New York, New York, 10065
Recruiting
Research Site
Newport Beach, California, 92663
Recruiting
Research Site
Newport News, Virginia, 23606
Terminated
Research Site
Newton, Kansas, 67114
Terminated
Research Site
Norfolk, Virginia, 23504
Recruiting
Research Site
Norman, Oklahoma, 73071
Recruiting
Research Site
North Hollywood, California, 91602
Terminated
Research Site
Ocala, Florida, 34470
Recruiting
Research Site
Ogden, Utah, 84405
Recruiting
Research Site
Oklahoma City, Oklahoma, 73134
Recruiting
Research Site
Olive Branch, Mississippi, 38654
Recruiting
Research Site
Omaha, Nebraska, 68134
Terminated
Research Site
Orlando, Florida, 32807
Recruiting
Research Site
Orlando, Florida, 32819
Recruiting
Research Site
Orlando, Florida, 32825
Recruiting
Research Site
Ormond Beach, Florida, 32174
Recruiting
Research Site
Oxon Hill, Maryland, 20745
Recruiting
Research Site
Paducah, Kentucky, 42001
Terminated
Research Site
Paris, Texas, 75462
Recruiting
Research Site
Peachtree Corners, Georgia, 30092
Withdrawn
Research Site
Pembroke Pines, Florida, 33024
Suspended
Research Site
Philadelphia, Pennsylvania, 19107
Recruiting
Research Site
Philadelphia, Pennsylvania, 19140
Recruiting
Research Site
Phoenix, Arizona, 85006
Terminated
Research Site
Pierre, South Dakota, 57501
Withdrawn
Research Site
Plano, Texas, 75024
Terminated
Research Site
Plano, Texas, 75093
Recruiting
Research Site
Plantation, Florida, 33324
Recruiting
Research Site
Pomona, California, 91768
Recruiting
Research Site
Potomac, Maryland, 20854
Terminated
Research Site
Raleigh, North Carolina, 27612
Suspended
Research Site
Rapid City, South Dakota, 57701
Recruiting
Research Site
Richmond, Virginia, 23219
Recruiting
Research Site
Richmond, Virginia, 23226
Terminated
Research Site
Roseburg, Oregon, 97471
Withdrawn
Research Site
Sacramento, California, 95823
Recruiting
Research Site
Sacramento, California, 95831
Recruiting
Research Site
Salisbury, North Carolina, 28144
Terminated
Research Site
Salt Lake City, Utah, 84107
Terminated
Research Site
San Bernardino, California, 92408
Terminated
Research Site
San Diego, California, 92111
Terminated
Research Site
San Dimas, California, 91773
Withdrawn
Research Site
Santa Ana, California, 92704
Withdrawn
Research Site
Savannah, Georgia, 31406
Recruiting
Research Site
Sheffield, Alabama, 35660
Withdrawn
Research Site
Shreveport, Louisiana, 71105
Recruiting
Research Site
Sioux City, Iowa, 51106
Recruiting
Research Site
Sioux Falls, South Dakota, 57104
Recruiting
Research Site
Southfield, Michigan, 48034
Recruiting
Research Site
Southfield, Michigan, 48075
Recruiting
Research Site
Spartanburg, South Carolina, 29303
Recruiting
Research Site
Spokane, Washington, 99218
Recruiting
Research Site
St Louis, Missouri, 63104
Recruiting
Research Site
St Louis, Missouri, 63136
Terminated
Research Site
St. Petersburg, Florida, 33713
Recruiting
Research Site
St. Petersburg, Florida, 33713
Suspended
Research Site
Statesville, North Carolina, 28625
Recruiting
Research Site
Statesville, North Carolina, 28677
Withdrawn
Research Site
Suffolk, Virginia, 23435
Recruiting
Research Site
Sun City Center, Florida, 33573
Terminated
Research Site
Tamarac, Florida, 33321
Suspended
Research Site
Tamarac, Florida, 33321
Recruiting
Research Site
Tampa, Florida, 33606
Recruiting
Research Site
Tampa, Florida, 33607
Suspended
Research Site
Tampa, Florida, 33625
Terminated
Research Site
Tarzana, California, 91356
Recruiting
Research Site
Tempe, Arizona, 85281
Suspended
Research Site
Tempe, Arizona, 85283
Terminated
Research Site
The Bronx, New York, 10455
Recruiting
Research Site
Thousand Oaks, California, 91360
Recruiting
Research Site
Toledo, Ohio, 43617
Withdrawn
Research Site
Toms River, New Jersey, 08755
Recruiting
Research Site
Tucker, Georgia, 30084
Recruiting
Research Site
Tucson, Arizona, 85710
Recruiting
Research Site
Tucson, Arizona, 85715
Recruiting
Research Site
Tullahoma, Tennessee, 37388
Recruiting
Research Site
Tulsa, Oklahoma, 74133
Recruiting
Research Site
Union, South Carolina, 29379
Recruiting
Research Site
Union City, New Jersey, 07087
Withdrawn
Research Site
Valparaiso, Indiana, 46383
Recruiting
Research Site
Van Nuys, California, 91405
Withdrawn
Research Site
Vestal, New York, 13850
Terminated
Research Site
Victoria, Texas, 77901
Terminated
Research Site
Vista, California, 92081
Recruiting
Research Site
Waco, Texas, 76708
Recruiting
Research Site
Washington D.C., District of Columbia, 20016
Terminated
Research Site
West Jordan, Utah, 84088
Terminated
Research Site
West Valley City, Utah, 84120
Recruiting
Research Site
Westminster, California, 92683
Suspended
Research Site
Wichita, Kansas, 67218
Recruiting
Research Site
Wichita Falls, Texas, 76308
Terminated
Research Site
Wilmington, North Carolina, 28412
Terminated
Research Site
Winfield, Illinois, 60190
Recruiting
Research Site
Winston-Salem, North Carolina, 27104
Recruiting
Research Site
Wylie, Texas, 75098
Recruiting
Research Site
Zachary, Louisiana, 70791
Recruiting

Other trials in United States

China98 sites, 80 recruiting

Research Site
Anning, 650000
Recruiting
Research Site
Anyang, 455001
Recruiting
Research Site
Baotou, 014040
Recruiting
Research Site
Baotou, 14010
Recruiting
Research Site
Beijing, 101100
Terminated
Research Site
Beijing, 10730
Withdrawn
Research Site
Changsha, 410004
Completed
Research Site
Changsha, 410005
Recruiting
Research Site
Changsha, 410015
Recruiting
Research Site
Changsha, 430033
Recruiting
Research Site
Changzhi, 46000
Recruiting
Research Site
Chengdu, 610031
Recruiting
Research Site
Chengdu, 610072
Recruiting
Research Site
Chengdu, 610500
Recruiting
Research Site
Chengdu, 611130
Recruiting
Research Site
Chifeng, 024000
Withdrawn
Research Site
Chizhou, 247099
Recruiting
Research Site
Chongqing, 400010
Recruiting
Research Site
Chongqing, 401320
Recruiting
Research Site
Chongqing, 408400
Recruiting
Research Site
Daqing, 163000
Recruiting
Research Site
Dazhou, 635000
Recruiting
Research Site
Foshan, 528000
Recruiting
Research Site
Fuzhou, 350001
Recruiting
Research Site
Guangzhou, 510000
Recruiting
Research Site
Guangzhou, 510120
Recruiting
Research Site
Guangzhou, 510145
Withdrawn
Research Site
Guangzhou, 510163
Recruiting
Research Site
Guangzhou, 510530
Recruiting
Research Site
Haikou, 570311
Active, not recruiting
Research Site
Hangzhou, 310006
Recruiting
Research Site
Hefei, 230000
Recruiting
Research Site
Hefei, 230061
Recruiting
Research Site
Heze, 274099
Recruiting
Research Site
Hohhot, 010010
Recruiting
Research Site
Hohhot, 750306
Recruiting
Research Site
Huizhou, 516001
Recruiting
Research Site
Huizhou, 516002
Recruiting
Research Site
Jiaozuo, 454002
Withdrawn
Research Site
Jinhua, 321099
Recruiting
Research Site
Jining, 272029
Recruiting
Research Site
Kaifeng, 475000
Withdrawn
Research Site
Langfang, 065000
Recruiting
Research Site
Lanzhou, 730000
Active, not recruiting
Research Site
Lishui, 323000
Recruiting
Research Site
Liuzhou, 545006
Recruiting
Research Site
Nanchang, 330006
Recruiting
Research Site
Nanchang, 330009
Recruiting
Research Site
Nanjing, 210009
Recruiting
Research Site
Nanyang, 473005
Recruiting
Research Site
Pingxiang, 337055
Recruiting
Research Site
Qingdao, 266011
Recruiting
Research Site
Qingyuan, 511518
Recruiting
Research Site
Ruian, 325299
Recruiting
Research Site
Sanya, 572000
Active, not recruiting
Research Site
Shanghai, 200025
Recruiting
Research Site
Shanghai, 200240
Recruiting
Research Site
Shanghai, 200433
Terminated
Research Site
Shanghai, 201199
Recruiting
Research Site
Shantou, 515041
Recruiting
Research Site
Shaoxing, 312000
Completed
Research Site
Shenyang, 110022
Recruiting
Research Site
Shenyang, 110032
Recruiting
Research Site
Shenzhen, 518001
Recruiting
Research Site
Shenzhen, 518020
Recruiting
Research Site
Shihezi, 832008
Withdrawn
Research Site
Shijiazhuang, 50051
Recruiting
Research Site
Siping, 136000
Recruiting
Research Site
Suining Shi, 629000
Recruiting
Research Site
Taicang, 215400
Recruiting
Research Site
Taiyuan, 030001
Recruiting
Research Site
Taiyuan, 030012
Recruiting
Research Site
Taiyuan, 030032
Recruiting
Research Site
Taizhou, 318000
Recruiting
Research Site
Ürümqi, 831118
Active, not recruiting
Research Site
Weifang, 261000
Recruiting
Research Site
Wenzhou, 325027
Recruiting
Research Site
Xi'an, 710006
Withdrawn
Research Site
Xiamen, 361004
Recruiting
Research Site
Xiangtan, 411100
Recruiting
Research Site
Xianyang, 750004
Active, not recruiting
Research Site
Xingtai, 054899
Recruiting
Research Site
Xinxiang, 453002
Recruiting
Research Site
Xinxiang, 453100
Recruiting
Research Site
Xuzhou, 221000
Recruiting
Research Site
Xuzhou, 221009
Recruiting
Research Site
Yangzhou, 225000
Recruiting
Research Site
Yangzhou, 225001
Recruiting
Research Site
Yinchuan, 750001
Active, not recruiting
Research Site
Yinchuan, 750004
Withdrawn
Research Site
Zaozhuang, 277102
Recruiting
Research Site
Zhangzhou, 363000
Recruiting
Research Site
Zhengzhou, 450000
Recruiting
Research Site
Zhengzhou, 450006
Recruiting
Research Site
Zhuhai, 519099
Recruiting
Research Site
Zhumadian, 463000
Recruiting
Research Site
Zhuzhou, 412007
Recruiting
Research Site
Zigong, 643000
Recruiting

Other trials in China

Germany52 sites, 40 recruiting

Research Site
Ahrensburg, 22926
Recruiting
Research Site
Augsburg, 86150
Recruiting
Research Site
Bamberg, 96049
Recruiting
Research Site
Berlin, 10625
Recruiting
Research Site
Berlin, 10629
Recruiting
Research Site
Berlin, 10787
Recruiting
Research Site
Berlin, 10961
Recruiting
Research Site
Berlin, 12157
Recruiting
Research Site
Berlin, 12159
Recruiting
Research Site
Berlin, 12203
Recruiting
Research Site
Berlin, 12627
Recruiting
Research Site
Berlin, 13187
Recruiting
Research Site
Bonn, 53127
Withdrawn
Research Site
Bremen, 28215
Withdrawn
Research Site
Bremen, 28259
Withdrawn
Research Site
Cottbus, 03050
Recruiting
Research Site
Dachau, 85221
Terminated
Research Site
Darmstadt, 64283
Recruiting
Research Site
Deggingen, 73326
Withdrawn
Research Site
Dresden, 01069
Terminated
Research Site
Essen, 45127
Recruiting
Research Site
Essen, 45355
Terminated
Research Site
Frankfurt, 60596
Recruiting
Research Site
Hamburg, 22335
Recruiting
Research Site
Hamburg, 22459
Recruiting
Research Site
Hanover, 30449
Recruiting
Research Site
Hanover, D-30173
Recruiting
Research Site
Heidelberg, 69115
Withdrawn
Research Site
Ibbenbueren, 49477
Recruiting
Research Site
Karlsruhe, 76137
Terminated
Research Site
Landsberg, 86899
Recruiting
Research Site
Leipzig, 04157
Recruiting
Research Site
Leipzig, 04177
Recruiting
Research Site
Leipzig, 04299
Recruiting
Research Site
Lübeck, 23552
Recruiting
Research Site
Mainz, 55128
Recruiting
Research Site
Marburg, 35037
Recruiting
Research Site
Moers, 47441
Recruiting
Research Site
München, 80336
Recruiting
Research Site
Offenbach, 63065
Recruiting
Research Site
Offenbach, 63069
Withdrawn
Research Site
Peine, 31224
Recruiting
Research Site
Rheine, 48431
Recruiting
Research Site
Riesa, 01587
Recruiting
Research Site
Rosenheim, 83022
Recruiting
Research Site
Solingen, 42699
Completed
Research Site
Wallerfing, 94574
Recruiting
Research Site
Weißenburg, 91781
Withdrawn
Research Site
Wermsdorf, 04779
Recruiting
Research Site
Wiesbaden, 65183
Recruiting
Research Site
Wiesbaden, 65189
Recruiting
Research Site
Witten, 58452
Recruiting

Other trials in Germany

Poland40 sites, 30 recruiting

Research Site
Bialystok, 15-044
Recruiting
Research Site
Bialystok, 15-879
Recruiting
Research Site
Bydgoszcz, 85-796
Recruiting
Research Site
Chęciny, 26-060
Recruiting
Research Site
Chojnice, 89-600
Recruiting
Research Site
Częstochowa, 42-217
Recruiting
Research Site
Inowrocław, 88-100
Recruiting
Research Site
Karczew, 05-480
Recruiting
Research Site
Katowice, 40-081
Recruiting
Research Site
Katowice, 40-648
Recruiting
Research Site
Kielce, 25-426
Recruiting
Research Site
Kielce, 25-751
Withdrawn
Research Site
Krakow, 31-501
Recruiting
Research Site
Krakow, 31-513
Recruiting
Research Site
Libiąż, 32-590
Recruiting
Research Site
Lodz, 91-363
Recruiting
Research Site
Lodz, 92-003
Withdrawn
Research Site
Lubin, 59-300
Withdrawn
Research Site
Lublin, 20-011
Recruiting
Research Site
Lublin, 20-601
Recruiting
Research Site
Ostrowiec Świętokrzyski, 27-400
Withdrawn
Research Site
Piaseczno, 05-500
Recruiting
Research Site
Płock, 09-407
Recruiting
Research Site
Poznan, 60-192
Recruiting
Research Site
Poznan, 61-578
Terminated
Research Site
Rzeszów, 35-205
Recruiting
Research Site
Sieradz, 98-200
Suspended
Research Site
Skórzewo, 60-185
Recruiting
Research Site
Słupsk, 76-200
Withdrawn
Research Site
Sochaczew, 96-500
Recruiting
Research Site
Sosnowiec, 41-200
Withdrawn
Research Site
Sosnowiec, 41-208
Recruiting
Research Site
Szczecin, 70-111
Suspended
Research Site
Torun, 87-100
Recruiting
Research Site
Ustroń, 43-450
Recruiting
Research Site
Warsaw, 00-215
Recruiting
Research Site
Warsaw, 00-719
Recruiting
Research Site
Warsaw, 04-501
Terminated
Research Site
Wroclaw, 53-673
Recruiting
Research Site
Wroclaw, 54-239
Recruiting

Other trials in Poland

Brazil39 sites, 32 recruiting

Research Site
Belo Horizonte, 30110-934
Withdrawn
Research Site
Belo Horizonte, 30150-221
Recruiting
Research Site
Belo Horizonte, 30220-140
Recruiting
Research Site
Blumenau, 89030-101
Completed
Research Site
Brasília, 70200-730
Recruiting
Research Site
Brasília, 70390-700
Recruiting
Research Site
Brasília, 70712-903
Recruiting
Research Site
Brasília, 71681-603
Withdrawn
Research Site
Campina Grande do Sul, 83.430-000
Recruiting
Research Site
Campinas, 13060-080
Recruiting
Research Site
Caxias do Sul, 95070-560
Withdrawn
Research Site
Curitiba, 80030-110
Recruiting
Research Site
Curitiba, 80230-130
Recruiting
Research Site
Curitiba, 80810-050
Recruiting
Research Site
Fortaleza, 60125-000
Completed
Research Site
Ijuí, 98700-000
Recruiting
Research Site
Juiz de Fora, 36033-318
Completed
Research Site
Mossoró, 59603-020
Recruiting
Research Site
Natal, 59020-500
Recruiting
Research Site
Niterói, 24020-096
Recruiting
Research Site
Passo Fundo, 99010-120
Recruiting
Research Site
Porto Alegre, 90035-903
Recruiting
Research Site
Porto Alegre, 90035074
Recruiting
Research Site
Porto Alegre, 9061-000
Recruiting
Research Site
Porto Alegre, 91350-200
Recruiting
Research Site
Recife, 50740-465
Recruiting
Research Site
Rio de Janeiro, 20551-030
Recruiting
Research Site
Rio de Janeiro, 22281-100
Withdrawn
Research Site
Salvador, 40170-130
Recruiting
Research Site
Santo André, 09080-110
Recruiting
Research Site
São Bernardo do Campo, 09715090
Recruiting
Research Site
São Bernardo do Campo, 09750-420
Recruiting
Research Site
São José do Rio Preto, 15090-000
Recruiting
Research Site
São Paulo, 04012-180
Recruiting
Research Site
São Paulo, 05403-000
Recruiting
Research Site
Serra, 29160-750
Recruiting
Research Site
Sorocaba, 18040-425
Recruiting
Research Site
Volta Redonda, 27258-000
Recruiting
Research Site
Votuporanga, 15501-405
Recruiting

Other trials in Brazil

Bulgaria33 sites, 24 recruiting

Research Site
Burgas, 8000
Recruiting
Research Site
Dobrich, 9300
Withdrawn
Research Site
Dupnitsa, 2600
Withdrawn
Research Site
Dupnitsa, 2602
Recruiting
Research Site
Haskovo, 6300
Recruiting
Research Site
Kozloduy, 3320
Withdrawn
Research Site
Montana, 3400
Recruiting
Research Site
Panagyurishte, 4500
Recruiting
Research Site
Pazardzhik, 4400
Recruiting
Research Site
Pernik, 2300
Recruiting
Research Site
Pleven, 5800
Recruiting
Research Site
Pleven, 5800
Withdrawn
Research Site
Plovdiv, 4002
Recruiting
Research Site
Plovdiv, 4003
Recruiting
Research Site
Plovdiv, 4004
Withdrawn
Research Site
Plovdiv, 4023
Recruiting
Research Site
Rousse, 7000
Recruiting
Research Site
Rousse, 7002
Recruiting
Research Site
Sandanski, 2800
Recruiting
Research Site
Sevlievo, 5403
Withdrawn
Research Site
Sliven, 8800
Withdrawn
Research Site
Sliven, 8800
Recruiting
Research Site
Sofia, 1000
Withdrawn
Research Site
Sofia, 1000
Recruiting
Research Site
Sofia, 1202
Recruiting
Research Site
Sofia, 1618
Recruiting
Research Site
Sofia, 1756
Recruiting
Research Site
Stara Zagora, 6003
Recruiting
Research Site
Varna, 9000
Withdrawn
Research Site
Varna, 9000
Recruiting
Research Site
Vidin, 3700
Recruiting
Research Site
Vratsa, 3000
Recruiting
Research Site
Yambol, 8600
Recruiting

Other trials in Bulgaria

France30 sites, 25 recruiting

Research Site
Aix-en-Provence, 13616
Recruiting
Research Site
Aurillac, 15000
Recruiting
Research Site
Bayonne, 64100
Withdrawn
Research Site
Bayonne, 64100
Recruiting
Research Site
Biarritz, 64200
Withdrawn
Research Site
Blois, 41016
Recruiting
Research Site
Brest, 29200
Recruiting
Research Site
Brest, 29609
Recruiting
Research Site
Cannes, 06414
Recruiting
Research Site
Cherbourg, 50102
Recruiting
Research Site
Créteil, 94000
Recruiting
Research Site
La Tronche, 38700
Recruiting
Research Site
Laval, 53015
Recruiting
Research Site
Le Coudray, 28630
Recruiting
Research Site
Lomme, Cedex 59462
Recruiting
Research Site
Lyon, 69317
Recruiting
Research Site
Marseille, 13003
Recruiting
Research Site
Marseille, 13015
Recruiting
Research Site
Mulhouse, 68100
Withdrawn
Research Site
Paris, 75651
Withdrawn
Research Site
Paris, 75679
Recruiting
Research Site
Pessac, 33604
Recruiting
Research Site
Pringy, 74374
Recruiting
Research Site
Quint-Fonsegrives, 31130
Recruiting
Research Site
Reims, 51092
Recruiting
Research Site
Roscoff, 29680
Terminated
Research Site
Strasbourg, 67091
Recruiting
Research Site
Vandœuvre-lès-Nancy, 54511
Recruiting
Research Site
Vannes, 56017
Recruiting
Research Site
Villeurbanne, 69100
Recruiting

Other trials in France

United Kingdom26 sites, 14 recruiting

Research Site
Bicester, OX26 6AT
Recruiting
Research Site
Bollington, SK10 5JH
Recruiting
Research Site
Bradford, BD13 2GD
Active, not recruiting
Research Site
Cardiff, CF37 2DR
Recruiting
Research Site
Chesterfield, S40 4AA
Recruiting
Research Site
Corby, NN17 2UR
Active, not recruiting
Research Site
Cottingham, HU16 5JQ
Withdrawn
Research Site
Fowey, PL23 1DT
Recruiting
Research Site
Glasgow, G4 0SF
Active, not recruiting
Research Site
Hounslow, TW4 7NR
Recruiting
Research Site
Liverpool, L14 3PE
Recruiting
Research Site
London, EC1M 6BQ
Completed
Research Site
London, NW3 2QG
Active, not recruiting
Research Site
London, SW1P 2PF
Recruiting
Research Site
Manchester, M8 5RB
Recruiting
Research Site
Newquay, TR7 1RU
Active, not recruiting
Research Site
North Somerset, BS23 3HQ
Recruiting
Research Site
Northallerton, DL7 8AW
Recruiting
Research Site
Norwich, NR1 1RB
Withdrawn
Research Site
Nottingham, NG9 6DX
Withdrawn
Research Site
Perth, PH1 1NX
Withdrawn
Research Site
Poole, BH16 5PW
Recruiting
Research Site
Sheffield, S9 5DH
Active, not recruiting
Research Site
Torbay, TQ1 4QX
Recruiting
Research Site
Whitney, OX29 4QB
Recruiting
Research Site
Witney, OX28 6JS
Active, not recruiting

Other trials in United Kingdom

Hungary23 sites, 14 recruiting

Research Site
Balatonfüred, 8230
Withdrawn
Research Site
Békéscsaba, H-5600
Recruiting
Research Site
Budapest, 1044
Recruiting
Research Site
Budapest, 1121
Recruiting
Research Site
Budapest, 1203
Withdrawn
Research Site
Debrecen, 4032
Recruiting
Research Site
Edelény, 3780
Recruiting
Research Site
Encs, 3860
Withdrawn
Research Site
Gödöllő, 2100
Withdrawn
Research Site
Gyöngyös - Mátraháza, 3200
Completed
Research Site
Hajdúnánás, 4080
Recruiting
Research Site
Kalocsa, 6300
Recruiting
Research Site
Komádi, 4138
Recruiting
Research Site
Monor, 2200
Withdrawn
Research Site
Pécs, 7626
Withdrawn
Research Site
Püspökladány, 4150
Recruiting
Research Site
Százhalombatta, 2440
Recruiting
Research Site
Szeged, 6724
Withdrawn
Research Site
Székesfehérvár, 8000
Withdrawn
Research Site
Szolnok, 5000
Recruiting
Research Site
Tapolca, 8300
Recruiting
Research Site
Törökbálint, 2045
Recruiting
Research Site
Vajszló, 7838
Recruiting

Other trials in Hungary

Canada22 sites, 19 recruiting

Research Site
Ajax, Ontario, L1S 2J5
Recruiting
Research Site
Calgary, Alberta, T3R 1W7
Recruiting
Research Site
Guelph, Ontario, N1H 1B1
Recruiting
Research Site
Hamilton, Ontario, L8L 5G4
Recruiting
Research Site
Kelowna, British Columbia, V1Y 1Z9
Recruiting
Research Site
Kingston, Ontario, K7L 2V7
Recruiting
Research Site
Kingston, Ontario, K7M 4E7
Recruiting
Research Site
Montreal, Quebec, H4A 3J1
Recruiting
Research Site
Québec, Quebec, G1G 5X1
Recruiting
Research Site
Québec, Quebec, G1V 4G5
Recruiting
Research Site
Québec, Quebec, G1W 4R4
Recruiting
Research Site
Québec, Quebec, G3K 2P8
Completed
Research Site
Richmond, British Columbia, V6V 2L1
Recruiting
Research Site
Saint-Charles-Borromée, Quebec, J6E 2B4
Recruiting
Research Site
Saskatoon, Saskatchewan, S7N 0W8
Withdrawn
Research Site
Sherwood Park, Alberta, T8L 0N2
Recruiting
Research Site
Sydney, Nova Scotia, B1M 0A1
Recruiting
Research Site
Thunder Bay, Ontario, P7B 7C7
Recruiting
Research Site
Toronto, Ontario, M5T 3A9
Withdrawn
Research Site
Trois-Rivières, Quebec, G8T 7A1
Recruiting
Research Site
Trois-Rivières, Quebec, G9A 4P3
Recruiting
Research Site
Winnipeg, Manitoba, R3L 1Z5
Recruiting

Other trials in Canada

India21 sites, 15 recruiting

Research Site
Ahmedabad, 380015
Recruiting
Research Site
Ahmedabad, 382421
Recruiting
Research Site
Aligarh, 202002
Recruiting
Research Site
Belagavi, 590010
Recruiting
Research Site
Calicut, 673 008
Recruiting
Research Site
Chandigarh, 160012
Withdrawn
Research Site
Dehradun, 248001
Recruiting
Research Site
Delhi, 110029
Recruiting
Research Site
Dwārka, 110075
Recruiting
Research Site
Hyderabad, 500068
Recruiting
Research Site
Jaipur, 302017
Recruiting
Research Site
Kolkata, 700014
Withdrawn
Research Site
Kolkata, 700073
Recruiting
Research Site
Mangalore, 575003
Withdrawn
Research Site
Mumbai, 400008
Withdrawn
Research Site
Nagpur, 441108
Recruiting
Research Site
New Delhi, 110005
Withdrawn
Research Site
New Delhi, 110029
Withdrawn
Research Site
Pune, 411062
Recruiting
Research Site
Telangana, 500004
Recruiting
Research Site
Vijayawada, 520 008
Recruiting

Other trials in India

Japan21 sites, 21 recruiting

Research Site
Chūōku, 103-0027
Recruiting
Research Site
Fujieda-shi, 426-8677
Recruiting
Research Site
Fukuoka, 814-0180
Recruiting
Research Site
Kitakyushu, 802-0052
Recruiting
Research Site
Kobe, 651-0072
Recruiting
Research Site
Kure-shi, 737-0193
Recruiting
Research Site
Kure-shi, 737-8505
Recruiting
Research Site
Kyoto, 607-8062
Recruiting
Research Site
Minoh, 562-0003
Recruiting
Research Site
Mizunami-shi, 509-6134
Recruiting
Research Site
Okayama, 702-8055
Recruiting
Research Site
Osaka, 530-0012
Recruiting
Research Site
Osaka, 545-8586
Recruiting
Research Site
Osaki-shi, 989-6183
Recruiting
Research Site
Sendai, 980-8574
Recruiting
Research Site
Shinjuku-ku, 160-8582
Recruiting
Research Site
Shinjuku-ku, 162-8655
Recruiting
Research Site
Takamatsu, 761-8073
Recruiting
Research Site
Yamagata, 990-8533
Recruiting
Research Site
Yanagawa-shi, 832-0059
Recruiting
Research Site
Yokohama, 234-0054
Recruiting

Other trials in Japan

Peru19 sites, 14 recruiting

Research Site
El Agustino, LIMA 10
Withdrawn
Research Site
Lima, 15023
Recruiting
Research Site
Lima, 15023
Withdrawn
Research Site
Lima, 15024
Recruiting
Research Site
Lima, 15036
Withdrawn
Research Site
Lima, 15036
Recruiting
Research Site
Lima, 15038
Recruiting
Research Site
Lima, 15046
Withdrawn
Research Site
Lima, 15046
Recruiting
Research Site
Lima, 15088
Recruiting
Research Site
Lima, 15102
Recruiting
Research Site
Lima, 15131
Recruiting
Research Site
Lima, 15324
Recruiting
Research Site
Lima, 33
Recruiting
Research Site
Lima, L18
Withdrawn
Research Site
Lima, LIMA 01
Recruiting
Research Site
Lima, LIMA 1
Recruiting
Research Site
Lima, LIMA 21
Recruiting
Research Site
Piura, 20001
Recruiting

Other trials in Peru

Mexico18 sites, 14 recruiting

Research Site
Benito Juárez, 03650
Recruiting
Research Site
Chihuahua City, 31000
Recruiting
Research Site
Cuernavaca, 62290
Withdrawn
Research Site
Cuernavaca, 62290
Recruiting
Research Site
Culiacán, 80020
Recruiting
Research Site
Guadalajara, 44200
Recruiting
Research Site
Guadalajara, 44670
Recruiting
Research Site
Juriquilla, 76320
Withdrawn
Research Site
Mérida, 97130
Recruiting
Research Site
Metepec, 52170
Recruiting
Research Site
Mexico City, 03310
Withdrawn
Research Site
Monterrey, 64310
Recruiting
Research Site
Monterrey, 64460
Recruiting
Research Site
Oaxaca City, 68020
Recruiting
Research Site
Tijuana, 22010
Withdrawn
Research Site
Veracruz, 91910
Recruiting
Research Site
Xalapa, 91193
Recruiting
Research Site
Zapopan, 45138
Recruiting

Other trials in Mexico

Turkey (Türkiye)18 sites, 16 recruiting

Research Site
Adana, 01060
Recruiting
Research Site
Adana, 01330
Recruiting
Research Site
Afyonkarahisar, 03030
Recruiting
Research Site
Antalya, 07059
Recruiting
Research Site
Bursa, 16059
Recruiting
Research Site
Bursa, 16110
Recruiting
Research Site
Çanakkale, 17110
Recruiting
Research Site
Çankaya, 06700
Recruiting
Research Site
Isparta, 32260
Withdrawn
Research Site
Istanbul, 34785
Withdrawn
Research Site
Istanbul, 34844
Recruiting
Research Site
Izmir, 35330
Recruiting
Research Site
Izmir, 35965
Recruiting
Research Site
Kayseri, 38030
Recruiting
Research Site
Kocaeli, 41380
Recruiting
Research Site
Mersin, 33343
Recruiting
Research Site
Tekirdağ, 59030
Recruiting
Research Site
Zeytinburnu, 34020
Recruiting

Other trials in Turkey (Türkiye)

Spain17 sites, 13 recruiting

Research Site
Alicante, 03010
Recruiting
Research Site
Badia Del Vallès, 08214
Recruiting
Research Site
Barakaldo, 48903
Withdrawn
Research Site
Barcelona, 08017
Terminated
Research Site
Barcelona, 08840
Recruiting
Research Site
Castro Urdiales, 39700
Recruiting
Research Site
Córdoba, 14940
Recruiting
Research Site
Granada, 18014
Recruiting
Research Site
Madrid, 28031
Recruiting
Research Site
Málaga, 29010
Recruiting
Research Site
Marbella (Málaga), 29603
Recruiting
Research Site
Mataró, 08302
Withdrawn
Research Site
Mataró, 08303
Recruiting
Research Site
Palma, 07011
Recruiting
Research Site
Patraix, 46017
Recruiting
Research Site
Santa Cruz de Tenerife, 38010
Withdrawn
Research Site
Santiago de Compostela-Coruña, 15706
Recruiting

Other trials in Spain

Argentina16 sites, 16 recruiting

Research Site
Buenos Aires, 1425
Recruiting
Research Site
Buenos Aires, C1012AAR
Recruiting
Research Site
Buenos Aires, C1425BEN
Recruiting
Research Site
CABA, C1019ABS
Recruiting
Research Site
Ciudad Autónoma de Bs As, C1182ACD
Recruiting
Research Site
Ciudad de Buenos Aires, C1414AIF
Recruiting
Research Site
Ciudad de Buenos Aires, C1425AGC
Recruiting
Research Site
Florida, B1602DQD
Recruiting
Research Site
Mar del Plata, B7600GWV
Recruiting
Research Site
Mendoza, M5500CCG
Recruiting
Research Site
Ranelagh, 1886
Recruiting
Research Site
Rosario, 2000
Recruiting
Research Site
San Fernando, B1646EBJ
Recruiting
Research Site
San Juan Bautista, 1888
Recruiting
Research Site
San Miguel de Tucumán, 4000
Recruiting
Research Site
San Miguel de Tucumán, T4000CBC
Recruiting

Other trials in Argentina

Ukraine15 sites, 14 recruiting

Research Site
Chernivtsi, 58029
Recruiting
Research Site
Chernivtsі, 58002
Recruiting
Research Site
Ivano-Frankivsk, 76018
Recruiting
Research Site
Ivano-Frankivsk, 76019
Recruiting
Research Site
Kyiv, 02002
Recruiting
Research Site
Kyiv, 02081
Recruiting
Research Site
Kyiv, 03037
Recruiting
Research Site
Kyiv, 03680
Recruiting
Research Site
Lviv, 79016
Recruiting
Research Site
Ternopil, 46001
Recruiting
Research Site
Uzhhorod, 88002
Recruiting
Research Site
Uzhhorod, 88018
Recruiting
Research Site
Vinnytsia, 21001
Recruiting
Research Site
Vinnytsia, 21009
Withdrawn
Research Site
Vinnytsia, 21029
Recruiting

Other trials in Ukraine

Italy14 sites, 13 recruiting

Research Site
Ancona, 60100
Recruiting
Research Site
Florence, 50134
Recruiting
Research Site
Genoa, 16132
Recruiting
Research Site
Mestre, 30174
Recruiting
Research Site
Milan, 20123
Completed
Research Site
Naples, 80131
Recruiting
Research Site
Pavia, 27100
Recruiting
Research Site
Perugia, 06126
Recruiting
Research Site
Roma, 00128
Recruiting
Research Site
Roma, 00133
Recruiting
Research Site
Roma, 161
Recruiting
Research Site
Rome, 00189
Recruiting
Research Site
Siena, 53100
Recruiting
Research Site
Varese, 21100
Recruiting

Other trials in Italy

Philippines14 sites, 9 recruiting

Research Site
Dagupan, 2400
Recruiting
Research Site
Iloilo City, 5000
Recruiting
Research Site
Las Piñas, 1742
Recruiting
Research Site
Mabalacat, 2023
Withdrawn
Research Site
Manadaluyong City, 1552
Withdrawn
Research Site
Manila, 1000
Withdrawn
Research Site
Manila, 1000
Recruiting
Research Site
Marilao, 3019
Recruiting
Research Site
Puerto Princesa City, 5300
Recruiting
Research Site
Quezon City, 0870
Recruiting
Research Site
Quezon City, 1100
Recruiting
Research Site
Quezon City, 1109
Active, not recruiting
Research Site
Roxas City, 5800
Withdrawn
Research Site
Tondo, 1012
Recruiting

Other trials in Philippines

South Korea13 sites, 11 recruiting

Research Site
Anyang-si, 14068
Recruiting
Research Site
Busan, 49201
Recruiting
Research Site
Daegu, 42415
Recruiting
Research Site
Gwangju, 61469
Withdrawn
Research Site
Jeonju, 54907
Recruiting
Research Site
Seoul, 03312
Recruiting
Research Site
Seoul, 04763
Recruiting
Research Site
Seoul, 06591
Recruiting
Research Site
Seoul, 07061
Recruiting
Research Site
Seoul, 08308
Terminated
Research Site
Seoul, 143-729
Recruiting
Research Site
Uijeongbu-si, 11765
Recruiting
Research Site
Ulsan, 44033
Recruiting

Other trials in South Korea

Taiwan13 sites, 12 recruiting

Research Site
Changhua County, 500
Recruiting
Research Site
Kaohsiung City, 82445
Recruiting
Research Site
Kaohsiung City, TAIWAN
Recruiting
Research Site
Taichung, 40201
Recruiting
Research Site
Taichung, 404
Recruiting
Research Site
Taichung, 40705
Recruiting
Research Site
Taichung, 433004
Recruiting
Research Site
Tainan, 70403
Recruiting
Research Site
Taipei, 10002
Recruiting
Research Site
Taipei, 10449
Terminated
Research Site
Taoyuan, 00333
Recruiting
Research Site
Taoyuan City, 330
Recruiting
Research Site
Yunlin, 640
Recruiting

Other trials in Taiwan

Australia12 sites, 6 recruiting

Research Site
Birtinya, 4575
Recruiting
Research Site
Cairns, 4870
Withdrawn
Research Site
Chermside, 4032
Completed
Research Site
Coffs Harbour, 02450
Recruiting
Research Site
Dubbo, 2830
Recruiting
Research Site
Nedlands, 6009
Recruiting
Research Site
Port Macquarie, 2444
Withdrawn
Research Site
Spearwood, 6163
Completed
Research Site
St Albans, 3021
Completed
Research Site
St Albans, 3021
Recruiting
Research Site
Waitara, 2077
Recruiting
Research Site
Wangaratta, 3677
Withdrawn

Other trials in Australia

Sweden12 sites, 10 recruiting

Research Site
Gothenburg, 413 46
Withdrawn
Research Site
Gothenburg, 41345
Recruiting
Research Site
Höllviken, 236 51
Recruiting
Research Site
Kungsbacka, 43480
Recruiting
Research Site
Lund, 22242
Recruiting
Research Site
Örebro, 70185
Recruiting
Research Site
Stockholm, 117 27
Recruiting
Research Site
Stockholm, 11883
Recruiting
Research Site
Stockholm, 171 76
Recruiting
Research Site
Stockholm, 18288
Recruiting
Research Site
Umeå, 901 85
Withdrawn
Research Site
Uppsala, 752 33
Recruiting

Other trials in Sweden

Romania11 sites, 11 recruiting

Research Site
Bucharest, 011461
Recruiting
Research Site
Bucharest, 012363
Recruiting
Research Site
Bucharest, 050159
Recruiting
Research Site
Cluj-Napoca, 400371
Recruiting
Research Site
Leamna de Sus, 207129
Recruiting
Research Site
Negreşti-Oaş, 445200
Recruiting
Research Site
Oradea, 410176
Recruiting
Research Site
Târgu Mureş, 540098
Recruiting
Research Site
Timișoara, 300203
Recruiting
Research Site
Timișoara, 300310
Recruiting
Research Site
Timișoara, 300336
Recruiting

Other trials in Romania

Chile10 sites, 7 recruiting

Research Site
Curicó, 3341643
Recruiting
Research Site
Quillota, 2260000
Recruiting
Research Site
Santiago, 7500691
Suspended
Research Site
Santiago, 7691236
Recruiting
Research Site
Santiago, 7750495
Withdrawn
Research Site
Talca, 3465584
Recruiting
Research Site
Temuco, 4810345
Recruiting
Research Site
Victoria, 4720097
Recruiting
Research Site
Viña del Mar, 2540488
Recruiting
Research Site
Vitacura, 7630226
Terminated

Other trials in Chile

Greece10 sites, 9 recruiting

Research Site
Athens, 11521
Recruiting
Research Site
Athens, 11527
Recruiting
Research Site
Athens, 12462
Recruiting
Research Site
Athens, 15125
Recruiting
Research Site
Athens, 17562
Recruiting
Research Site
Athens, 18547
Withdrawn
Research Site
Ioannina, 45500
Recruiting
Research Site
Pátrai, 26500
Recruiting
Research Site
Thessaloniki, 57001
Recruiting
Research Site
Thessaloniki, 57010
Recruiting

Other trials in Greece

Thailand10 sites, 10 recruiting

Research Site
Bangkok, 10700
Recruiting
Research Site
Hat Yai, 90110
Recruiting
Research Site
Khlong Luang, 12120
Recruiting
Research Site
Muang, 22000
Recruiting
Research Site
Muang, 40002
Recruiting
Research Site
Muang, 50200
Recruiting
Research Site
Nonthaburi, 11000
Recruiting
Research Site
Ongkharak, 26120
Recruiting
Research Site
Phitsanulok, 65000
Recruiting
Research Site
Ratchathewi, 10400
Recruiting

Other trials in Thailand

Czechia9 sites, 6 recruiting

Research Site
Brandýs nad Labem, 250 01
Active, not recruiting
Research Site
Jindřichův Hradec, 377 01
Recruiting
Research Site
Olomouc, 772 00
Completed
Research Site
Olomouc, 772 00
Active, not recruiting
Research Site
Ostrava, 702 00
Recruiting
Research Site
Prague, 110 00
Recruiting
Research Site
Prague, 140 46
Recruiting
Research Site
Rokycany, 337 22
Recruiting
Research Site
Tábor, 390 03
Recruiting

Other trials in Czechia

Colombia8 sites

Research Site
Armenia, 630004
Withdrawn
Research Site
Barranquilla, 080020
Withdrawn
Research Site
Bogotá, 111411
Withdrawn
Research Site
Manizales, 17001
Withdrawn
Research Site
Medellín, 050025
Withdrawn
Research Site
Medellín, 050030
Withdrawn
Research Site
Piedecuesta, 681017
Withdrawn
Research Site
Rionegro, 054047
Withdrawn

Other trials in Colombia

Malaysia8 sites, 7 recruiting

Research Site
Alor Star, 05460
Recruiting
Research Site
Kajang, 43000
Recruiting
Research Site
Kuala Lumpur, 50586
Recruiting
Research Site
Kuala Pilah, 72000
Recruiting
Research Site
Sandakan, 90000
Recruiting
Research Site
Sarawak Miri, 98000
Recruiting
Research Site
Seremban, 70300
Withdrawn
Research Site
Sibu, 96000
Recruiting

Other trials in Malaysia

Slovakia8 sites, 6 recruiting

Research Site
Bratislava, 949 01
Recruiting
Research Site
Brezno, 977 01
Recruiting
Research Site
Humenné, 066 01
Recruiting
Research Site
Košice, 04022
Recruiting
Research Site
Kráľovský Chlmec, 077 01
Withdrawn
Research Site
Levice, 93401
Recruiting
Research Site
Prešov, 081 81
Withdrawn
Research Site
Topoľčany, 955 01
Recruiting

Other trials in Slovakia

Serbia7 sites, 7 recruiting

Research Site
Belgrade, 11000
Recruiting
Research Site
Belgrade, 11040
Recruiting
Research Site
Belgrade, 11080
Recruiting
Research Site
Kamenitz, 21204
Recruiting
Research Site
Kragujevac, 34000
Recruiting
Research Site
Niš, 18108
Recruiting
Research Site
Novi Sad, 21000
Recruiting

Other trials in Serbia

Denmark6 sites, 6 recruiting

Research Site
Aalborg, 9000
Recruiting
Research Site
Esbjerg, 6700
Recruiting
Research Site
Hvidovre, 2650
Recruiting
Research Site
København NV, 2400
Recruiting
Research Site
Næstved, 4700
Recruiting
Research Site
Vejle, 7100
Recruiting

Other trials in Denmark

Austria5 sites, 4 recruiting

Research Site
Bad Ischl, 4820
Recruiting
Research Site
Braunau am Inn, 5280
Recruiting
Research Site
Feldbach, 8330
Recruiting
Research Site
Graz, 8036
Recruiting
Research Site
Vienna, 1090
Withdrawn

Other trials in Austria

Finland5 sites, 4 recruiting

Research Site
Helsinki, 00100
Recruiting
Research Site
Helsinki, 00980
Recruiting
Research Site
Kangasala, 36200
Recruiting
Research Site
Kuopio, 70100
Recruiting
Research Site
Turku, 20100
Withdrawn

Other trials in Finland

Norway4 sites, 3 recruiting

Research Site
Kongsberg, 3612
Recruiting
Research Site
Lørenskog, 1478
Recruiting
Research Site
Skedsmokorset, N-2020
Recruiting
Research Site
Trondheim, 7030
Withdrawn

Other trials in Norway

About this study

Official title: A Randomized, Double-blind, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS)

Read the detailed description

This is a Phase III randomized, double-blind, parallel group, multi-center event-driven study comparing BGF MDI 320/14.4/9.6 μg BID with GFF MDI 14.4/9.6 μg BID in participants with COPD who are at risk of a cardiopulmonary event.

Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Being tested: BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg
Medical subject headings: Pulmonary Disease, Chronic Obstructive

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

BGF MDI 320/14.4/9.6 μgDrug
Budesonide, glycopyrronium, and formoterol fumarate pressurized inhalation suspension
GFF MDI 14.4/9.6 μgDrug
Glycopyrronium and formoterol fumarate pressurized inhalation suspension

Study groups in NCT06283966
Study group	Role	What they receive
BGF arm	Experimental	BGF MDI 320/14.4/9.6 μg BID Receives: Drug: BGF MDI 320/14.4/9.6 μg
GFF arm	Experimental	GFF MDI 14.4/9.6 μg BID Receives: Drug: GFF MDI 14.4/9.6 μg

What is being measured

The primary outcome is the main question the study is designed to answer.

Time to first severe cardiac or COPD event
Evaluate the effect of combination triple therapy (BGF MDI 320/14.4/9.6 μg) compared with dual bronchodilator therapy (GFF MDI 14.4/9.6 μg) on cardiopulmonary outcomes.
Measured: Up to 3 years

Secondary outcomes (6)

Time to first severe COPD exacerbation event
Evaluate the effect of combination triple therapy (BGF MDI 320/14.4/9.6 μg) compared with dual bronchodilator therapy (GFF MDI 14.4/9.6 μg) on severe COPD exacerbations.
Measured: Up to 3 years
Time to first severe cardiac event
Evaluate the effect of combination triple therapy (BGF MDI 320/14.4/9.6 μg) compared with dual bronchodilator therapy (GFF MDI 14.4/9.6 μg) on severe cardiac outcomes.
Measured: Up to 3 years
Time to cardiopulmonary death
Evaluate the effect of combination triple therapy (BGF MDI 320/14.4/9.6 μg) compared with dual bronchodilator therapy (GFF MDI 14.4/9.6 μg) on cardiopulmonary deaths.
Measured: Up to 3 years
Moderate/severe COPD exacerbation rate
Evaluate the effect of combination triple therapy (BGF MDI 320/14.4/9.6 μg) compared with dual bronchodilator therapy (GFF MDI 14.4/9.6 μg) on moderate/severe COPD exacerbations.
Measured: Over time, up 3 years
Time to Myocardial Infarction (MI) hospitalization or cardiac death
Evaluate the effect of combination triple therapy (BGF MDI 320/14.4/9.6 μg) compared with dual bronchodilator therapy (GFF MDI 14.4/9.6 μg) on the time to MI hospitalization (or cardiac death).
Measured: Up to 3 years
Time to Heart Failure (HF) acute healthcare visit/hospitalization or cardiac death
Evaluate the effect of combination triple therapy (BGF MDI 320/14.4/9.6 μg) compared with dual bronchodilator therapy (GFF MDI 14.4/9.6 μg) on the time to HF acute healthcare visit/hospitalization (or cardiac death).
Measured: Up to 3 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

21 Feb 20243 Dec 2027

First posted28 Feb 2024
Study start21 Feb 2024
Primary completion3 Dec 2027 (estimated)
Study completion3 Dec 2027 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for COPD (Chronic Obstructive Pulmonary Disease)Studies of the same condition, open and under way.
More trials run by AstraZenecaThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 3
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Model description: This is a Phase III randomized, double-blind, parallel group, multi-center event-driven study comparing BGF MDI 320/14.4/9.6 μg BID with GFF MDI 14.4/9.6 μg BID in participants with COPD who are at risk of a cardiopulmonary event.
Masking: Quadruple blind
Who is masked: Participant, Care provider, Investigator, Outcomes assessor
Enrolment: 5,250 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT06283966
Sponsor's protocol ID: D5989C00001
Other IDs: 2023-507407-59-00, 2023
Acronym: THARROS
Status last verified: Sep 2026
First submitted: 21 Feb 2024
Last updated: 2 Oct 2026
Results posted: No
Data monitoring committee: Yes
FDA-regulated drug: Yes
FDA-regulated device: No
Individual data sharing: Yes: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Interested in taking part?

AstraZeneca Clinical Study Information Center

1-877-240-9479

information.center@astrazeneca.com

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See sites and contacts

Recruiting
Lungs on Fire: Wildfire Smoke, Incident Diseases, Susceptible Populations, and Community Values in Canada
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Not yet recruitingPhase 2
Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients
COPD, Chronic Obstructive Pulmonary Disease (COPD)
RecruitingObservational study
Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
Chronic Obstructive Pulmonary Disease (COPD), Smoking
RecruitingPhase 2
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD)
RecruitingPhase 2
A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)
COPD (Chronic Obstructive Pulmonary Disease)

All COPD (Chronic Obstructive Pulmonary Disease) trials

Study at a glance

From the registry record, last updated by the sponsor on 2 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Randomized, Double-blind, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS)
ClinicalTrials.gov ID: NCT06283966
Acronym / sponsor ID: THARROS / D5989C00001
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Phase: Phase 3
Study type: Interventional
Recruitment status: Recruiting
Enrolment: 5,250 participants (estimated)
Lead sponsor: AstraZenecaIndustry (pharma, biotech, devices)
Study start: 21 Feb 2024 (actual)
Primary completion: 3 Dec 2027 (estimated)
Study completion: 3 Dec 2027 (estimated)
First posted: 28 Feb 2024 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind (participant, care provider, investigator, outcomes assessor)
Number of arms: 2
Model description: This is a Phase III randomized, double-blind, parallel group, multi-center event-driven study comparing BGF MDI 320/14.4/9.6 μg BID with GFF MDI 14.4/9.6 μg BID in participants with COPD who are at risk of a cardiopulmonary event.

Arm	Type	Receives
BGF arm	Experimental	Drug: BGF MDI 320/14.4/9.6 μgBGF MDI 320/14.4/9.6 μg BID
GFF arm	Experimental	Drug: GFF MDI 14.4/9.6 μgGFF MDI 14.4/9.6 μg BID

Who may qualify

Ages: 40 to 80 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (32 listed)

Male or female participants must be 40 to 80 years of age inclusive, at the time of signing
the ICF.
Demonstrate acceptable MDI administration technique at Visit 1 (V1) and Visit 2 (V2)
A diagnosis of COPD confirmed by a post-bronchodilator FEV1/FVC ratio < 70%
at V1.

Key exclusion criteria (19 listed)

Active diagnosis of asthma within the past 5 years (previous diagnosis as a child or adolescent are eligible), asthma-COPD overlap, or any other chronic respiratory disease other than COPD such as alpha-1 antitrypsin deficiency, active tuberculosis, lung fibrosis, sarcoidosis, interstitial lung disease, and pulmonary hypertension.
End-stage renal disease requiring renal replacement therapy
History of heart or lung transplant or actively listed for heart or lung transplant.
Implanted left ventricular assist device or implant anticipated in < 3 months.
History of lung cancer and/or treatment for lung cancer within the 5 years prior to Visit 1.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
BGF MDI 320/14.4/9.6 μgBudesonide, glycopyrronium, and formoterol fumarate pressurized inhalation suspension	Drug	BGF arm
GFF MDI 14.4/9.6 μgGlycopyrronium and formoterol fumarate pressurized inhalation suspension	Drug	GFF arm

Primary outcome

Time to first severe cardiac or COPD event
Time frame: Up to 3 years
Evaluate the effect of combination triple therapy (BGF MDI 320/14.4/9.6 μg) compared with dual bronchodilator therapy (GFF MDI 14.4/9.6 μg) on cardiopulmonary outcomes.

6 secondary outcomes

Time to first severe COPD exacerbation event
Time frame: Up to 3 years
Time to first severe cardiac event
Time frame: Up to 3 years
Time to cardiopulmonary death
Time frame: Up to 3 years
Moderate/severe COPD exacerbation rate
Time frame: Over time, up 3 years
Time to Myocardial Infarction (MI) hospitalization or cardiac death
Time frame: Up to 3 years
Time to Heart Failure (HF) acute healthcare visit/hospitalization or cardiac death
Time frame: Up to 3 years

Results and safety

This study is still under way. Results are not available in the source record yet.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 2 Oct 2026.
Individual participant dataSharing planned: Yes. Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Related trials for COPD (Chronic Obstructive Pulmonary Disease)

Recruiting
Lungs on Fire: Wildfire Smoke, Incident Diseases, Susceptible Populations, and Community Values in Canada
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Not yet recruitingPhase 2
Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients
COPD, Chronic Obstructive Pulmonary Disease (COPD)
RecruitingObservational study
Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
Chronic Obstructive Pulmonary Disease (COPD), Smoking
RecruitingPhase 2
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD)
RecruitingPhase 2
A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)
COPD (Chronic Obstructive Pulmonary Disease)

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.

AstraZeneca Clinical Study Information Center contact

1-877-240-9479

information.center@astrazeneca.com

922 sites in 37 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing BGF MDI 320/14.4/9.6 μg and GFF MDI 14.4/9.6 μg in people with COPD (Chronic Obstructive Pulmonary Disease), run by AstraZeneca at 922 sites in 37 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 32 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 2 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 922 sites in United States, China, Germany, Poland, Brazil and 32 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact AstraZeneca Clinical Study Information Center (1-877-240-9479, information.center@astrazeneca.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time to first severe cardiac or COPD event (time frame: Up to 3 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06283966.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2026.